Video

Using Artificial Intelligence in Drug Discovery with Jackie Hunter

In this latest podcast Jackie Hunter, Director at BenevolentAI, is interviewed by Vox Markets discussing the fundamentals of AI application within drug development.

AI enables scientists to be their most productive, and the scope of AI application for healthcare today is huge. During this podcast, Jackie sheds light on where she believes some of the critical areas are where we can create impact.

In the broader healthcare system, AI is only beginning to scratch the surface of the value it can create and there are already a range of proof points across the spectrum from radiology, pathology or patient stratification showing how it can help deliver diagnostics much more rapidly and increase efficiencies.

In drug development, the pharmaceutical industry has been slower to adopt AI technology and it is only now that the industry is realising the potential AI can have. For example, one great impact AI can create is in early drug discovery, more specifically in target identification where the process has not evolved for a good fifty years. AI can also help identify better biomarkers and ways in which we can assess how the drug will behave in clinical trials.

Embedding AI in the drug development process will help improve the way drugs are brought to market.

More Posts

You Might Also Like

News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021